Table 1:
Baseline characteristics for patients enrolled in the randomized clinical trial evaluating benefit of probe-based near infrared autofluorescence (NIRAF) detection during parathyroidectomy
| Overall | NIRAF (Intervention) | No NIRAF (Control) | |
|---|---|---|---|
|
| |||
| Preoperative patient variables | |||
|
| |||
| Age (years) | 58.3 ± 14.5 | 58.6 ± 14.6 | 59.8 ± 14.4 |
|
| |||
| Sex | |||
| Male | 35 (22) | 18 (22) | 17 (21) |
| Female | 125 (78) | 62 (78) | 63 (79) |
|
| |||
| Race | |||
| White | 147 (92) | 73 (91.25) | 74 (92.5) |
| Black | 11 (7) | 5 (6.25) | 6 (7.5) |
| Asian | 1 (0.5) | 1 (1.25) | 0 (0) |
| Other | 1 (0.5) | 1 (1.25) | 0 (0) |
|
| |||
| Ethnicity | |||
| Non-Hispanic | 159 (99) | 79 (99) | 80 (100) |
| Hispanic | 1 (1) | 1 (1) | 0 (0) |
| BMI | 30.85 ± 7.59 | 30.77 ± 7.52 | 30.94 ± 7.72 |
|
| |||
| Diagnosis | |||
| Primary Sporadic HPT | 143 (89) | 72 (90) | 71 (89) |
| Persistent HPT | 12 (7) | 3 (4) | 9 (11) |
| Recurrent HPT | 1 (1) | 1 (1) | 0 (0) |
| MEN1 | 2 (1) | 2 (3) | 0 (0) |
| Parathyroid carcinoma | 1 (1) | 1 (1) | 0 (0) |
| Lithium induced HPT | 1 (1) | 1 (1) | 0 (0) |
|
| |||
| Preoperative Calcium (mg/dL) | 11.112 ± 0.712 | 11.115 ± 0.689 | 11.112 ± 0.712 |
|
| |||
| Preoperative PTH (pg/mL) | 157.9 ± 112.7 | 152.3 ± 79.8 | 163.6 ± 139.0 |
|
| |||
| Preoperative Vitamin D | 38.1 ± 18.2 | 36.7 ± 16.0 | 39.6 ± 20.5 |
|
| |||
| Procedure by Intention | |||
| Focused | 51 (32) | 27 (34) | 24 (30) |
| Bilateral | 109 (68) | 53 (66) | 56 (70) |
Continuous variables presented as mean ± standard deviation. Categorical or ordinal variables presented as number (percent of population); HPT, hyperparathyroidism; PTH, parathyroid hormone